– Revenue up 5.8% to HK$876.5 Million, Profit up 3.8% to HK$ 163.4 million – 16.7% Dividend Surge – Continued…
Browsing: HealthCare
ADC pipeline with multiple products entering key clinical stages Revenue increased by 350% year-on-year Focusing on the field of tumor…
In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies,…
Australian Company Announces Landmark Paper Showing Cyclodextrin Therapy Reverses Heart Disease, Hailed as ‘Greatest Development Since Statins’ Cholrem Pty Ltd,…
Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults…
– Declares Special Dividend of HK15 Cents per Share to Celebrate 25th Anniversary – Leveraging Strategic Global Footprint and Innovative…
Everest Medicines (HKG: 1952.HK, Everest) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New…
Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for…
Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical…
SGX Catalist-listed AsiaMedic Limited (the “Company” and, together with its subsidiaries, the “Group”) announced its unaudited financial results for the…
New agreement reinforces Formerra’s strategy to support high-performance applications with advanced polymer solutions across multiple markets. Formerra, a leader in…
– Global Leadership Solidified as Multi-Segment Commercialization Accelerates Cryofocus Medtech (Shanghai) Co., Ltd. (“Cryofocus” or the “Company,” Stock Code: 6922.HK),…
Everest Medicines (HKG: 1952) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R).…
A major breakthrough in surgical embodied intelligence in Robot-Assisted Surgery (RAS) has been achieved in Hong Kong, China. At a press conference…
TruMerit, a worldwide leader in international credentials evaluation to support health worker careers, today introduced the Certified Global Nurse (CGN), the…
Everest Medicines (HKG: 1952) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved…
Everest Medicines (HKG: 1952) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9…
Traveler Care, a breakthrough medical dispatch platform that brings urgent care directly to travelers in hotels, Airbnbs, and vacation rentals,…
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly…
SHANGHAI, July 25, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on…